Abstract
The risk prediction model included hair colour, nevus density, first-degree family history of melanoma, previous non-melanoma skin Study. Model calibration showed close agreement between predicted and observed numbers of incident melanomas across all deciles of predicted risk. In the external validation setting, there was higher net benefit when using the risk prediction model to classify individuals as high risk compared with classifying all individuals as high risk.
Conclusion and Relevance
The melanoma risk prediction model performs well, and may be useful in prevention interventions reliant on a risk assessment using self-assessed risk factors.
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Background
Melanoma incidence has been increasing in predominantly fair-skinned populations, with Australia having the world's highest rates.
1 Primary prevention measures, based on sun protection, are a priority for reducing the melanoma burden. 2 Risk prediction models have been proposed as a more accurate and informative way of communicating risk, 3 and may lead to better preventive behaviours among those at high risk. Additionally, risk stratification may assist in planning intervention trials and targeting population prevention interventions. 4 Most published melanoma risk prediction models have limited reporting of methods and results, and few have been externally validated. 5, 6 External validation evaluates model performance using independent data, and is important before routine clinical use. 7 We aimed to develop a model for incident first-primary cutaneous melanoma based on self-assessed risk factors from the Australian Melanoma Family Study 8 [ 16, 17) ). Lifetime (to 85 years of age) and 20-year absolute risks (P) for an individual aged a with relative risk r , was estimated using the Gail method 22 by (i)
calculating the attributable fraction (AF) from the distribution of relative risk among the cases 23 , (ii) multiplying the Australian age-specific melanoma incidence rates (h1*) by (1-AF)
to give h1, and (iii) using h2, the mortality rates from causes other than melanoma between 2007 to 2009 (eTable1) as shown in the following formula.
where in the summation, the smallest j value satisfies j-1= a, the largest j value satisfies j=a+ and the value of is the time interval over which we calculate the absolute risk, for example to calculate 20-year absolute risk =20. S1, the probability of remaining melanoma free up to age . j, was estimated by S1( j)=S1( j-1)exp(-5h1jrj), where S1(0)=1. S2, the probability of surviving competing risk up to age j, was estimated by S2( j)=S2( j-1)exp(-5h2), where S2(0)=1.
Model performance and validation
We evaluated model performance in the development dataset (internal validation) and externally using four independent validation datasets by assessing discrimination (the ability to distinguish between those with and without melanoma) using the area under the receiver operating characteristic curve (AUC), with values ranging from 0.5 (no better than chance) to 1 (perfect discrimination). 24 Additionally, we assessed calibration and clinical usefulness in the Swedish Women's Lifestyle and Health Cohort Study 15, 25 over 20 years of follow up, by examining the calibration plot, calibration slope, calibration-in-the-large, net benefit and decision curve (obtained from plotting the net benefit at different absolute risk thresholds).
The calibration plot depicts the observed and predicted numbers of incident melanomas by deciles of predicted risk. 26 The calibration-in-the-large (intercept) and calibration slope (slope) is obtained from plotting the log odds of predictions as the predictor, with an intercept of 0 and slope of 1 indicating perfect calibration. 26 Net benefit was calculated by weighing the true-positive against the false-positive classifications at different absolute risk thresholds, the relative weight of the true-positive to false-positive classifications is determined by the absolute risk threshold, with higher net benefit indicating greater clinical usefulness. 27 We used bootstrapping procedures with 1000 repetitions to estimate 95% confidence intervals.
Variables in the validation datasets were harmonized to those in the risk prediction model. Study, thus we assumed that none of its participants used sunbeds. Lifetime (to 85 years of age) and 20-year absolute risks were estimated using the Gail method. 22 We excluded validation study participants who had missing values for any of the predictor variables. 28 The total participants included in the analyses and missing rates are shown in eTable2. 
Results
The final melanoma risk prediction model included hair colour, nevus density, first-degree family history of melanoma, previous non-melanoma skin cancer and sunbed use, with red hair colour and nevus density the strongest predictors of risk (Table 1) In matched case-control studies, the distribution of risk factors among controls is more similar to the cases than to the general population. 31 We conducted sensitivity analyses to For discrimination, the model compared well to risk prediction models for melanoma and other cancers. Systematic reviews of melanoma risk prediction models have shown AUCs ranging from 0.62 to 0.86 on internal validation. 5, 32 In one of the few models with external validation, Fortes and colleagues reported an AUC of 0.79. 33 Discriminative performance tends to be higher when based on clinically measured nevi, 34 such as in the Fortes and colleagues model ; 33 probably because self-reports tend to underestimate nevus counts in comparison with clinical assessment. 35 AUCs of risk prediction models for other cancers ranged from 0.53 to 0.66 for breast cancer, 36 0.62 to 0.75 for colorectal cancer, 37,38 0.67 to 0.73 for lung cancer 39 and 0.52 to 0.93 for prostate cancer, 40 with poorer discrimination on external validation. 41 A strength of our study was the use of calibration and newer model performance measures:
net benefit and decision curve analyses using an independent cohort study. Previous melanoma risk prediction models that reported calibration used the Hosmer-Lemeshow test, which is sensitive to sample size 42 and has low power to detect overfitting of predictor effects. 24 Presenting the calibration plot, calibration-in-the large and calibration slope, as we have done, is the preferred method. 7, 26 To our knowledge, no other melanoma prediction model evaluated model performance using net benefit and decision curve analyses. 5, 32, 43 A few prediction models for other cancers have found, as we did, that using the model to classify individuals at high risk using reasonably low absolute risk thresholds had higher net benefit compared with classifying all individuals as high risk. [44] [45] [46] Based on net benefit analyses, our model is most useful at classifying individuals as high risk and warranting risk-based interventions if the 20-year absolute risk threshold is 1% or less. In use. For 20-year absolute risk thresholds set at 1% or less, using the model to classify individuals as high risk for risk-based interventions would be better than either assuming everyone is high risk (intervening) and assuming everyone is low risk (not intervening).
However, for 20-year absolute risk thresholds set above 1%, the model would be no better than assuming everyone is low risk (not intervening).
The choice of a risk threshold for intervention will likely vary depending on the efficacy and potential harms associated with the intervention and subsequent management for individuals classified as high risk. If the intervention and subsequent management has high efficacy and low potential harms, then the risk threshold for intervention will be low. In contrast, if the intervention and subsequent management has low efficacy and high potential harms, then the risk threshold for intervention will be high.
Direct comparison with previous melanoma risk prediction models and validation studies is difficult due to differences in the study designs, predictor variable definitions, data handling and reporting. It is a potential limitation that our model was developed using a dataset in which all melanoma cases were less than 40 years old (i.e. early-onset) at diagnosis. Table continued 
